Erlotinib with or without bevacizumab as a first‐line therapy for patients with advanced nonsquamous epidermal growth factor receptor‐positive non‐small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study

BACKGROUND: In the phase II JO25567 study (JapicCTI‐111390), erlotinib plus bevacizumab demonstrated a significant clinical benefit in Japanese patients with epidermal growth factor receptor mutation‐positive (EGFR+) non‐small cell lung cancer (NSCLC). Here, we present an exploratory analysis invest...

Descripción completa

Detalles Bibliográficos
Autores principales: Hosomi, Yukio, Seto, Takashi, Nishio, Makoto, Goto, Koichi, Yamamoto, Noboru, Okamoto, Isamu, Tajima, Kosei, Kajihara, Yusuke, Yamamoto, Nobuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346191/
https://www.ncbi.nlm.nih.gov/pubmed/35768976
http://dx.doi.org/10.1111/1759-7714.14541

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346191/
https://www.ncbi.nlm.nih.gov/pubmed/35768976
http://dx.doi.org/10.1111/1759-7714.14541

Ejemplares similares